Analysts Conflicted on These Healthcare Names: Daiichi Sankyo Company (OtherDSKYF), Inovio Pharmaceuticals (INO) and Molina Healthcare (MOH)
Jefferies Adjusts Daiichi Sankyo's Price Target to 6,600 Yen From 5,600 Yen, Keeps at Buy
Jefferies Adjusts Daiichi Sankyo's Price Target to 5,600 Yen From 4,800 Yen, Keeps at Buy
Jefferies Upgrades Daiichi Sankyo to Buy From Hold, Adjusts Price Target to 4,800 Yen From 4,300 Yen
Jefferies Adjusts Daiichi Sankyo's Price Target to 4,300 Yen From 3,900 Yen, Keeps at Hold
Jefferies Downgrades Daiichi Sankyo to Hold From Buy, Adjusts Price Target to 1,900 Yen From 2,000 Yen
Esperion Jumps 15% as BofA Double-upgrades Citing Near-term Upside
Esperion Extends Selloff as Daiichi Sankyo Dispute Prompts BofA Downgrade
Jefferies Adjusts Daiichi Sankyo's Price Target to 5,300 Yen From 4,300 Yen, Keeps at Buy
Gilead Upgraded to Equal Weight at Barclays on Strong Execution in HIV, Kite
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
No Data